Prognostic Significance of Volume-Based FDG PET/CT Parameters in Patients with Locally Advanced Pancreatic Cancer Treated with Chemoradiation Therapy
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: We investigated the prognostic role of volume-based parameters measured on 18F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography(PET/CT) scans in patients with locally advanced pancreatic cancer (LAPC) treated with chemoradiation therapy (CRT). Materials and Methods: We enrolled 60 patients with LAPC who underwent FDG PET/CT before CRT. Maximum standardizeduptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) of primary pancreatic cancers were measured on FDG PET/CT scans. Treatment response was evaluated according to the Response Evaluation Criteriain Solid Tumors. Survival analysis was performed using the Kaplan-Meier method, and Cox proportional hazard models were used to determine independent prognostic factors. Results: The progression-free survival (PFS), locoregional progression-free survival (LRFPS), and overall survival (OS) for this population were 6.2, 10.9, and 13.2 months, respectively. The overall treatment response rate was 16.7% at 4 weeks after CRT, and the disease control rate (DCR) was 80.0%. DCR was significantly higher in patients with low SUVmax, MTV, or TLG, and showed strong correlation with longer survival times. On univariate analysis, MTV and TLG were significant prognostic factors for PFS, LRPFS, and OS, together with pre-CRT and post-CRT CA19-9 levels. Multivariate analyses demonstrated that MTV togetherwith the pre-CRT CA19-9 level were independent prognostic factors for PFS, LRPFS,and OS, as was TLG for LRPFS and OS. Conclusion: MTV and the pre-CRT CA19-9 level provided independent prognostic information in patients with LAPC treated with CRT. Volume-based PET/CT parameters may be useful in identifying which subgroup of patients would benefit from radiation therapy as a part of CRT.
Abstract
Purpose: We investigated the prognostic role of volume-based parameters measured on 18F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography(PET/CT) scans in patients with locally advanced pancreatic cancer (LAPC) treated with chemoradiation therapy (CRT). Materials and Methods: We enrolled 60 patients with LAPC who underwent FDG PET/CT before CRT. Maximum standardizeduptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) of primary pancreatic cancers were measured on FDG PET/CT scans. Treatment response was evaluated according to the Response Evaluation Criteriain Solid Tumors. Survival analysis was performed using the Kaplan-Meier method, and Cox proportional hazard models were used to determine independent prognostic factors. Results: The progression-free survival (PFS), locoregional progression-free survival (LRFPS), and overall survival (OS) for this population were 6.2, 10.9, and 13.2 months, respectively. The overall treatment response rate was 16.7% at 4 weeks after CRT, and the disease control rate (DCR) was 80.0%. DCR was significantly higher in patients with low SUVmax, MTV, or TLG, and showed strong correlation with longer survival times. On univariate analysis, MTV and TLG were significant prognostic factors for PFS, LRPFS, and OS, together with pre-CRT and post-CRT CA19-9 levels. Multivariate analyses demonstrated that MTV togetherwith the pre-CRT CA19-9 level were independent prognostic factors for PFS, LRPFS,and OS, as was TLG for LRPFS and OS. Conclusion: MTV and the pre-CRT CA19-9 level provided independent prognostic information in patients with LAPC treated with CRT. Volume-based PET/CT parameters may be useful in identifying which subgroup of patients would benefit from radiation therapy as a part of CRT.
참고문헌 (35)
- Coupland VH, "Incidence and survival for hepatic, pancreatic and biliary cancers in England between 1998 and 2007", Cancer Epidemiol, 36, pp.e207~e214 (2012)
- Li D, "Pancreatic cancer", Lancet, 363, pp.1049~1057 (2004)
- Geer RJ, "Prognostic indicators for survival after resection of pancreatic adenocarcinoma", Am J Surg, 165, pp.68~72 (1993)
- Heinemann V, "Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials", Semin Oncol, 29(6 Suppl 20), pp.9~16 (2002)
- Willett CG, "Locally advanced pancreatic cancer", J Clin Oncol, 23, pp.4538~4544 (2005)
- Real FX, "A “catastrophic hypothesis” for pancreas cancer progression", Gastroenterology, 124, pp.1958~1964 (2003)
- "Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group", J Natl Cancer Inst, 80, pp.751~755 (1988)
- Chauffert B, "Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD", SFRO study, 2008, pp.19, 1592~1599
- Klaassen DJ, "Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study", J Clin Oncol, 3, pp.373~378 (1985)
- Hammel P, "Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: final results of the international phase III LAP 07 study", Pancreatology, 13, pp.S89~ (2013)
- Kauhanen SP, "A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography", computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer, 2009, pp.250, 957~963
- Topkan E, "Predictive value of metabolic 18FDG-PET response on outcomes in patients with locally advanced pancreatic carcinoma treated with definitive concurrent chemoradiotherapy", BMC Gastroenterol, 11, pp.123~ (2011)
- 최혜진, "Prognostic Value of 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients with Resectable Pancreatic Cancer", Yonsei Medical Journal, 54(6), pp.1377~1383 (2013), 연세대학교의과대학[DOI]
- Lee SM, "Improved Prognostic Value of Standardized Uptake Value Corrected for Blood Glucose Level in Pancreatic Cancer Using F-18 FDG PET", CLINICAL NUCLEAR MEDICINE, 36(5), pp.331~336 (2011), LIPPINCOTT WILLIAMS WILKINS
- Jae Pil Hwang, "Prognostic value of SUVmax measured by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography with Computed Tomography in Patients with Pancreatic Cancer", Nuclear Medicine and Molecular Imaging, 46(3), pp.207~214 (2012), 대한핵의학회
- Moon SY, "Predictive value of maximum standardized uptake value (SUVmax) on 18F-FDG PET", CT in patients with locally advanced or metastatic pancreatic cancer, 2013, pp.38, 778~783
- Fendler WP, "Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer", J Nucl Med, 54, pp.1202~1208 (2013)
- Oh JR, "Whole-body metabolic tumour volume of 18F-FDG PET", CT improves the prediction of prognosis in small cell lung cancer, 2012, pp.39, 925~935
- Ryu IS, "Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET", CT in salivary gland carcinomas, 2013, pp.54, 1032~1038
- Parlak C, "Prognostic value of gross tumor volume delineated by FDG-PET-CT based radiotherapy treatment planning in patients with locally advanced pancreatic cancer treated with chemoradiotherapy", Radiat Oncol, 7, pp.37~ (2012)
- Bjerregaard JK, "Prognostic factors for survival and resection in patients with initial nonresectable locally advanced pancreatic cancer treated with chemoradiotherapy", Int J Radiat Oncol Biol Phys, 83, pp.909~915 (2012)
- Haas M, "Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy", J Cancer Res Clin Oncol, 139, pp.681~689 (2013)
- Yang GY, "Change in CA 19-9 levels after chemoradiotherapy predicts survival in patients with locally advanced unresectable pancreatic cancer", J Gastrointest Oncol, 4, pp.361~369 (2013)
- Davison J, "PET-based primary tumor volumetric parameters and survival of patients with non-small cell lung carcinoma", AJR Am J Roentgenol, 200, pp.635~640 (2013)
- 문승환, "Prognostic Significance of Volume-Based PET Parameters in Cancer Patients", Korean Journal of Radiology, 14(1), pp.1~12 (2013), 대한영상의학회[DOI]
- Van de Wiele C, "Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours", Eur J Nucl Med Mol Imaging, 40, pp.290~301 (2013)
- Kang WJ, "Differentiation of mediastinal FDG uptake observed in patients with non-thoracic tumours", EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 31, pp.202~207 (2004), SPRINGER
- Nakamoto Y, "Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas", Cancer, 89, pp.2547~2554 (2000)
- Orlacchio A, "Solitary pulmonary nodules: morphological and metabolic characterisation by FDG-PET-MDCT", Radiol Med, 112, pp.157~173 (2007)
- Uto F, "Phantom study on radiotherapy planning using PET", CT--delineation of GTV by evaluating SUV, 2010, pp.51, 157~164
- Hazel JJ, "Multi-drug chemotherapy with and without radiation for carcinoma of the stomach and pancreas: a prospective randomized trial", J Can Assoc Radiol, 32, pp.164~165 (1981)
- Huguet F, "Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies", J Clin Oncol, 25, pp.326~331 (2007)
- Iacobuzio-Donahue CA, "DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer", J Clin Oncol, 27, pp.1806~1813 (2009)
- Crane CH, "Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4 (Dpc4) immunostaining with pattern of disease progression", J Clin Oncol, 29, pp.3037~3043 (2011)
- Park HH, "Inter-comparison of 18F-FDG PET", CT standardized uptake values in Korea, 2011, pp.69, 241~246